Literature DB >> 10025734

Lack of value of specific IgA detection in the postnatal diagnosis of congenital toxoplasmosis.

A K Faure1, H Fricker-Hidalgo, H Pelloux, C Bost-Bru, A Goullier-Fleuret, P Ambroise-Thomas.   

Abstract

To improve the performance of the postnatal diagnosis of congenital toxoplasmosis, we assessed the detection of IgA antibodies to Toxoplasma gondii by ELISA, compared with that of IgM by ELISA, ISAGA, and IFAT and neosynthesized antibodies using Western blot. From 1993 to 1996, IgA antibodies were detected using the Toxo IgA test (SFRI, Société Française de Recherches et d'Investissements, Bordeaux, France), in 195 serum and cord blood samples from 63 infants born to mothers who seroconverted during pregnancy. Eighteen infants had proven congenital toxoplasmosis (confirmed by the presence of IgG after 12 months of life) and 45 had no congenital toxoplasmosis (negativity of IgG after 6-12 months of life). The sensitivity of IgA detection by ELISA on serum and cord blood samples was 38.9 and 54.5% respectively, which is low when compared with the sensitivity of IgM detection by ISAGA (66.7% on serum samples, 90.9% on cord blood), ELISA (61.1% on sera, 81.8% on cord blood) and Western blot (83.3% on sera, 72.7% on cord blood). IgA antibodies were never detected by ELISA earlier than IgM or neosynthesized Ig (antibodies synthesized by infants). Thus, the detection of IgA antibodies by Toxo IgA is not useful in improving the diagnosis of congenital toxoplasmosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10025734      PMCID: PMC6808018          DOI: 10.1002/(sici)1098-2825(1999)13:1<27::aid-jcla5>3.0.co;2-y

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  17 in total

1.  [Decision analysis of congenital toxoplasmosis in the absence of exact knowledge of the treatment benefits and secondary effects].

Authors:  R Ecochard; G Landrivon; C Colin; P Creac'h; M Wallon; F Gandilhon; F Peyron; Y Matillon
Journal:  Rev Epidemiol Sante Publique       Date:  1996-04       Impact factor: 1.019

Review 2.  Teratogen update: congenital toxoplasmosis.

Authors:  R Lynfield; R B Eaton
Journal:  Teratology       Date:  1995-09

3.  Prenatal diagnosis of congenital toxoplasmosis: comparative value of fetal blood and amniotic fluid using serological techniques and cultures.

Authors:  H Fricker-Hidalgo; H Pelloux; F Muet; C Racinet; M Bost; A Goullier-Fleuret; P Ambroise-Thomas
Journal:  Prenat Diagn       Date:  1997-09       Impact factor: 3.050

4.  IgA antibodies for diagnosis of acute congenital and acquired toxoplasmosis.

Authors:  P Stepick-Biek; P Thulliez; F G Araujo; J S Remington
Journal:  J Infect Dis       Date:  1990-07       Impact factor: 5.226

5.  [Evaluation of the Vidas system for the serological diagnosis of toxoplasmosis].

Authors:  H Pelloux; P Ciapa; A Goullier-Fleuret; P Ambroise-Thomas
Journal:  Ann Biol Clin (Paris)       Date:  1993       Impact factor: 0.459

6.  [Congenital toxoplasmosis: contribution of postnatal biological follow-up].

Authors:  H Fricker-Hidalgo; H Pelloux; M Bost; A Goullier-Fleuret; P Ambroise-Thomas
Journal:  Presse Med       Date:  1996-12-07       Impact factor: 1.228

7.  Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group.

Authors:  N G Guerina; H W Hsu; H C Meissner; J H Maguire; R Lynfield; B Stechenberg; I Abroms; M S Pasternack; R Hoff; R B Eaton
Journal:  N Engl J Med       Date:  1994-06-30       Impact factor: 91.245

8.  Congenital toxoplasmosis: 10-year follow up.

Authors:  M Mombrò; C Perathoner; A Leone; M Nicocia; A Moiraghi Ruggenini; C Zotti; M A Lievre; C Fabris
Journal:  Eur J Pediatr       Date:  1995-08       Impact factor: 3.183

9.  Value of specific immunoglobulin A detection by two immunocapture assays in the diagnosis of toxoplasmosis.

Authors:  F Foudrinier; C Marx-Chemla; D Aubert; A Bonhomme; J M Pinon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-07       Impact factor: 3.267

10.  Diagnosis of congenital toxoplasmosis by immunoblotting and relationship with other methods.

Authors:  B F Chumpitazi; A Boussaid; H Pelloux; C Racinet; M Bost; A Goullier-Fleuret
Journal:  J Clin Microbiol       Date:  1995-06       Impact factor: 5.948

View more
  5 in total

1.  Prevalence of congenital Toxoplasma gondii infection among newborns from the Poznań region of Poland: validation of a new combined enzyme immunoassay for Toxoplasma gondii-specific immunoglobulin A and immunoglobulin M antibodies.

Authors:  M Paul; E Petersen; J Szczapa
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

2.  Assessment of the IgA immunosorbent agglutination assay for the diagnosis of congenital toxoplasmosis on a series of 145 toxoplasmic seroconversions.

Authors:  J B Murat; A Souvignet; H Fricker-Hidalgo; M P Brenier-Pinchart; C Bost-Bru; H Pelloux
Journal:  Clin Vaccine Immunol       Date:  2015-02-11

3.  Strategy for diagnosis of congenital toxoplasmosis: evaluation of methods comparing mothers and newborns and standard methods for postnatal detection of immunoglobulin G, M, and A antibodies.

Authors:  J M Pinon; H Dumon; C Chemla; J Franck; E Petersen; M Lebech; J Zufferey; M H Bessieres; P Marty; R Holliman; J Johnson; V Luyasu; B Lecolier; E Guy; D H Joynson; A Decoster; G Enders; H Pelloux; E Candolfi
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

4.  Diagnosis of Congenital Toxoplasmosis: No Benefit of IgA Antibody Detection by Platelia ELISA in a Tricentric Evaluation.

Authors:  Maude F Lévêque; Sahar Albaba; Neïla Arrada; Marine Avignon; Milène Sasso; Judith Fillaux; Laurence Lachaud
Journal:  J Clin Microbiol       Date:  2022-05-02       Impact factor: 11.677

5.  The necessity of confirmatory testing in serodiagnosis of toxoplasmosis in iran.

Authors:  Mehrzad Saraei; Seyedeh Zeinab Fattahi; Mojtaba Shahnazi; Afshin Afshari; Safar Ali Alizadeh; Hassan Jahanihashemi
Journal:  Iran J Parasitol       Date:  2013-10       Impact factor: 1.012

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.